Jian-Jun Zhao1, Peng-Jie Chen2, Rui-Qin Duan3, Ke-Ji Li3, Yu-Zhong Wang3, Yong Li4. 1. Department of Surgery, The Fourth Hospital of Hebei Medical University Shijiazhuang, 050011, Hebei, China ; Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China. 2. Department of Neurology, Handan Central Hospital Handan, 056001, Hebei, China. 3. Department of Urology, Affiliated Hospital of Hebei University of Engineering Handan, 056002, Hebei, China. 4. Department of Surgery, The Fourth Hospital of Hebei Medical University Shijiazhuang, 050011, Hebei, China.
Abstract
INTRODUCTION: MicroRNAs (miRNAs) are noncoding RNAs that regulate multiple cellular processes during cancer progression. MiR-630 has recently been identified to be involved in tumorigenesis of several cancers such as lung cancer and gastric cancer. However, the regulation of miR-630 in clear cell renal cell carcinoma (ccRCC) has not yet been reported before. METHODS: Expression of miR-630 was evaluated by quantitative real-time PCR in tumour and their normal matched tissues in n = 92 ccRCC patients, and its association with overall survival of patients was analyzed by statistical analysis. RESULTS: The expression level of miR-630 was significantly higher in renal cancer in comparison to normal matched tissue (P < 0.05). It is also proved that miR-630 expression was to be associated with renal cancer histologic grade, lymphnode metastasis, distant metastasis (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that high miR-630 expression was associated with poor prognosis in ccRCC patients. miR-630 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis. CONCLUSIONS: The study proves for the first time that miR-630 is upregulated in a majority of ccRCC patients. It also shows that miR-630 expression is an independent prognostic factor for patients with renal cancer, which might be a potential valuable biomarker for ccRCC.
INTRODUCTION: MicroRNAs (miRNAs) are noncoding RNAs that regulate multiple cellular processes during cancer progression. MiR-630 has recently been identified to be involved in tumorigenesis of several cancers such as lung cancer and gastric cancer. However, the regulation of miR-630 in clear cell renal cell carcinoma (ccRCC) has not yet been reported before. METHODS: Expression of miR-630 was evaluated by quantitative real-time PCR in tumour and their normal matched tissues in n = 92 ccRCC patients, and its association with overall survival of patients was analyzed by statistical analysis. RESULTS: The expression level of miR-630 was significantly higher in renal cancer in comparison to normal matched tissue (P < 0.05). It is also proved that miR-630 expression was to be associated with renal cancer histologic grade, lymphnode metastasis, distant metastasis (P < 0.05). In addition, the Kaplan-Meier survival curves revealed that high miR-630 expression was associated with poor prognosis in ccRCC patients. miR-630 expression was an independent prognostic marker of overall ccRCC patient survival in a multivariate analysis. CONCLUSIONS: The study proves for the first time that miR-630 is upregulated in a majority of ccRCC patients. It also shows that miR-630 expression is an independent prognostic factor for patients with renal cancer, which might be a potential valuable biomarker for ccRCC.
Authors: Lorenzo Galluzzi; Eugenia Morselli; Ilio Vitale; Oliver Kepp; Laura Senovilla; Alfredo Criollo; Nicolas Servant; Caroline Paccard; Philippe Hupé; Thomas Robert; Hugues Ripoche; Vladimir Lazar; Annick Harel-Bellan; Philippe Dessen; Emmanuel Barillot; Guido Kroemer Journal: Cancer Res Date: 2010-02-09 Impact factor: 12.701
Authors: R Montironi; A Santinelli; R Pomante; R Mazzucchelli; P Colanzi; A L Filho; M Scarpelli Journal: Virchows Arch Date: 2000-07 Impact factor: 4.064
Authors: Hiroshi Miyamoto; Jeremy S Miller; Daniel A Fajardo; Thomas K Lee; George J Netto; Jonathan I Epstein Journal: Pathol Int Date: 2010-01 Impact factor: 2.534
Authors: Zhong Jiang; Peigou G Chu; Bruce A Woda; Qin Liu; K C Balaji; Kenneth L Rock; Chin-Lee Wu Journal: Clin Cancer Res Date: 2008-09-01 Impact factor: 12.531
Authors: Pierre I Karakiewicz; Alberto Briganti; Felix K-H Chun; Quoc-Dien Trinh; Paul Perrotte; Vincenzo Ficarra; Luca Cindolo; Alexandre De la Taille; Jacques Tostain; Peter F A Mulders; Laurent Salomon; Richard Zigeuner; Tommaso Prayer-Galetti; Denis Chautard; Antoine Valeri; Eric Lechevallier; Jean-Luc Descotes; Herve Lang; Arnaud Mejean; Jean-Jacques Patard Journal: J Clin Oncol Date: 2007-04-10 Impact factor: 44.544